Eltrombopag-Associated Hepatobiliary Laboratory Abnormalities

Incidence and Severity of Liver Dysfunction

• Eltrombopag definitively causes hepatobiliary laboratory abnormalities and hepatotoxicity, with increased alanine aminotransferase (ALT) being one of the most common adverse events occurring in approximately 5-13% of patients 1, 2

High-Risk Populations Requiring Caution

• Eltrombopag should be used with extreme caution in patients with preexisting liver disease, with close monitoring of liver function tests, as recommended by the American College of Hematology 1, 2, 3

Monitoring Requirements

• Close monitoring of liver function tests is mandatory during eltrombopag therapy, as emphasized by the American College of Hematology 1, 2, 3

Important Caveats

• The risk-benefit assessment must account for the indication, and the American College of Gastroenterology may recommend against routine use of eltrombopag in chronic liver disease due to excess thrombotic events, although this specific guideline is not provided 4